Dynorphinl_13 is a potent inhibitor of electrically-induced contractions in the guinea pig ileum, where it has the properties of ×-(ethylketocyclazocine) type opioids. In the brain, however, it has no analgesic potency, yet inhibits that induced by morphine. To gain further insight into its mechanism of action in the latter system, we tested its ability to compete for the binding of several opiates to brain membranes in vitro. Dynorphinl_13 inhibited the binding of all ligands examined, including dihydromorphine, D-Ala2-o-LeuS-enkephalin, ethylketacyclazocine (EKC) and naloxone. In all cases, it reduced the number of high affinity sites and, in the case of EKC, it also increased the K a. We conclude that the mechanism of dynorphin inhibition is not simple rapidly reversible competition and is certainly not identical with respect to all opiate ligands.
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Since the discovery of the enkephalins in 1975 by Hughes et al.6 , the existence of several other opioid peptides has been reported, most notably, fl-endorphin, (fl-EP), dynorphinl_]7 and a-neo-endorphin. All of these peptides have been shown to exhibit opiate-like activities in in vitro bioassay systems such as the guinea pig ileum longitudinal muscle preparation, although only fl-EP, has morphine-like antinociceptive activity 2. From in vitro studies, it appears that morphine and its analogs probably bind to a subclass of opiate receptors (~), which is distinct from that which binds enkephalins (6), although both classes of ligand also have affinity to the other receptor and are capable to displacing each other. Dynorphin]_13, on the other hand, has been demonstrated to be much more potent than morphine in guinea pig ileum longitudinal muscle preparation where it behaves most like members of a third iigand class (×), of which ethylketocyclazocine is the prototype 3. Paradoxically, dynorphinl_~3 is not analgesic and can antagonize morphine-induced analgesia in vivo 4.5, effects different from those of a typical × agonist. In order to illuminate the relationship of this peptide to various classes of opiate ligands, we have examined its ability to compete in in vitro binding with the agonists dihydromorphine (DHM) (~), DAla2-D-LeuS-enkephalin (DADLE) (6) and ethylketocyclazocine (KC) (×), as well as the antagonist naloxone.
Tritiated D-Ala2-D-LeuS-enkephalin (31 Ci/mmol) and ethylketocyclazocine (15 Ci/mmol) were purchased from New England Nuclear (Boston, MA). Tritiated dihydromorphine (70-85 Ci/mmol) and naloxone (40 Ci/mmoi) were from Amersham (Arlington Heights, IL).
Male ICR mice (25 _+ 2 g) were obtained from Simonsen Labs (Gilroy, CA). The animals were sacrificed by dislocation and the brains (minus cerebellum and medulla) pooled. Binding studies were performed in crude synaptosomal (P2) fractions. The samples contained 25 mM HEPES, pH 7.7, 1.4 mg protein and different concentrations of [3H]ligand in a final volume of 2 ml and were incubated at 37 °C in a shaking incubator for 30 min unless otherwise stated. In saturation experiments, the samples were cooled before filtering on Whatman GF/B filters under 15 mm Hg of vacuum. The filters were washed with 2 × 5 ml of ice-cold HEPES buffer, 5 mM, pH 7.7 and counted
